发布求助
文献互助 智能选刊 最新文献

Oncoscience最新文献

筛选
英文 中文
Targeting carbohydrate metabolism in colorectal cancer - synergy between DNA-damaging agents, cannabinoids, and intermittent serum starvation. 针对结直肠癌的碳水化合物代谢--DNA 损伤剂、大麻素和间歇性血清饥饿之间的协同作用。
Oncoscience Pub Date : 2024-11-12 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.611
Viktoriia Cherkasova, Olga Kovalchuk, Igor Kovalchuk
{"title":"Targeting carbohydrate metabolism in colorectal cancer - synergy between DNA-damaging agents, cannabinoids, and intermittent serum starvation.","authors":"Viktoriia Cherkasova, Olga Kovalchuk, Igor Kovalchuk","doi":"10.18632/oncoscience.611","DOIUrl":"https://doi.org/10.18632/oncoscience.611","url":null,"abstract":"<p><p>Chemotherapy is a therapy of choice for many cancers. However, it is often inefficient for long-term patient survival and is usually accompanied by multiple adverse effects. The adverse effects are mainly associated with toxicity to normal cells, frequently resulting in immune system depression, nausea, loss of appetite and metabolic changes. In this respect, the combination of chemotherapy with cannabinoids, especially non-psychoactive, such as cannabidiol, cannabinol and other minor cannabinoids, as well as terpenes, may become very useful. This is especially pertinent because the mechanisms of anticancer effects of cannabinoids on cancer cells are often different from conventional chemotherapeutics. In addition, cannabinoids help alleviate chemotherapy-induced adverse effects, regulate sleep and appetite, and are shown to have analgesic properties. Another component for achieving potential anti-cancer synergism is regulating nutrient availability and metabolism by calorie restriction and intermittent fasting in cancer cells. As tumours require a lot of energy to grow and because glucose is constantly available, malignant cells often opt to use glucose as a primary source of ATP production through substrate-level phosphorylation (fermentation) rather than through oxidative phosphorylation. Thus, periodic depletion of cancer cells of primary fuel, glucose, could result in a strong synergy in killing cancer cells by chemo- and possibly radiotherapy when combined with cannabinoids. This commentary will discuss what is known about such combinatorial treatments, including potential mechanisms and future protocols.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"99-105"},"PeriodicalIF":0.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer with brain metastasis. 一名 IV 期非小细胞肺癌脑转移患者对免疫疗法的完全和持久反应。
Oncoscience Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.609
Mafalda Costa, Helena Magalhães
{"title":"Complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer with brain metastasis.","authors":"Mafalda Costa, Helena Magalhães","doi":"10.18632/oncoscience.609","DOIUrl":"https://doi.org/10.18632/oncoscience.609","url":null,"abstract":"<p><p>Approximately 20% of lung cancer patients have brain metastasis at diagnosis, which is associated with a worse prognosis and a negative impact on quality of life. The emergence of new systemic treatment options such as immune checkpoint inhibitors (ICI) and targeted therapies changed the prognosis for stage IV lung cancer patients. However, the impact of local and systemic treatment sequencing in patients with stage IV lung cancer and brain metastasis is still unclear. We present the case of a 51-year-old man with stage IV non-small cell lung cancer and brain metastasis at diagnosis who underwent whole brain radiotherapy (WBRT) and achieved intracranial and extracranial complete response after second-line treatment with an ICI. Currently, the patient has an overall survival of 87 months and a progression-free survival of 73 months with an optimal quality of life. We hypothesized that treatment sequencing of WBRT and immunotherapy could explain this unexpected outcome.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"92-98"},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The challenge of weight gain in hormone receptor-positive breast cancer. 激素受体阳性乳腺癌患者体重增加的挑战。
Oncoscience Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.608
Terrence C Tsou, Avonne Connor, Jennifer Y Sheng
{"title":"The challenge of weight gain in hormone receptor-positive breast cancer.","authors":"Terrence C Tsou, Avonne Connor, Jennifer Y Sheng","doi":"10.18632/oncoscience.608","DOIUrl":"10.18632/oncoscience.608","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"67-68"},"PeriodicalIF":0.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular mechanism of PARP inhibitor resistance. PARP 抑制剂耐药性的分子机制。
Oncoscience Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.610
Yi Huang, Simin Chen, Nan Yao, Shikai Lin, Junyi Zhang, Chengrui Xu, Chenxuan Wu, Guo Chen, Danyang Zhou
{"title":"Molecular mechanism of PARP inhibitor resistance.","authors":"Yi Huang, Simin Chen, Nan Yao, Shikai Lin, Junyi Zhang, Chengrui Xu, Chenxuan Wu, Guo Chen, Danyang Zhou","doi":"10.18632/oncoscience.610","DOIUrl":"https://doi.org/10.18632/oncoscience.610","url":null,"abstract":"<p><p>Poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi) are the first-approved anticancer drug designed to exploit synthetic lethality. PARPi selectively kill cancer cells with homologous recombination repair deficiency (HRD), as a result, PARPi are widely employed to treated <i>BRCA1/2</i>-mutant ovarian, breast, pancreatic and prostate cancers. Currently, four PARPi including Olaparib, Rucaparib, Niraparib, and Talazoparib have been developed and greatly improved clinical outcomes in cancer patients. However, accumulating evidences suggest that required or <i>de novo</i> resistance emerged. In this review, we discuss the molecular mechanisms leading to PARPi resistances and review the potential strategies to overcome PARPi resistance.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"69-91"},"PeriodicalIF":0.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional information offers individualized adaptive cancer therapies. 功能信息可提供个性化的适应性癌症疗法。
Oncoscience Pub Date : 2024-07-19 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.607
R Craig Herndon
{"title":"Functional information offers individualized adaptive cancer therapies.","authors":"R Craig Herndon","doi":"10.18632/oncoscience.607","DOIUrl":"10.18632/oncoscience.607","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"65-66"},"PeriodicalIF":0.0,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization. 揭示骨髓瘤细胞内化的逆转录转座子衍生 DNA 邮政编码
Oncoscience Pub Date : 2024-07-13 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.606
Pavan Kumar Puvvula, Anthony Johnson, Leon Bernal-Mizrachi
{"title":"Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization.","authors":"Pavan Kumar Puvvula, Anthony Johnson, Leon Bernal-Mizrachi","doi":"10.18632/oncoscience.606","DOIUrl":"10.18632/oncoscience.606","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"58-64"},"PeriodicalIF":0.0,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma. 针对炎症因子进行化学预防和癌症拦截，以应对恶性间皮瘤。
Oncoscience Pub Date : 2024-05-23 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.605
Joseph R Testa, Yuwaraj Kadariya, Joseph S Friedberg
{"title":"Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma.","authors":"Joseph R Testa, Yuwaraj Kadariya, Joseph S Friedberg","doi":"10.18632/oncoscience.605","DOIUrl":"10.18632/oncoscience.605","url":null,"abstract":"<p><p>Mesothelioma is an incurable cancer of the mesothelial lining often caused by exposure to asbestos. Asbestos-induced inflammation is a significant contributing factor in the development of mesothelioma, and genetic factors also play a role in the susceptibility to this rapidly progressive and treatment-resistant malignancy. Consequently, novel approaches are urgently needed to treat mesothelioma and prevent or reduce the overall incidence of this fatal disease. In this research perspective, we review the current state of chemoprevention and cancer interception progress in asbestos-induced mesothelioma. We discuss the different preclinical mouse models used for these investigations and the inflammatory factors that may be potential targets for mesothelioma prevention. Preliminary studies with naturally occurring phytochemicals and synthetic agents are reviewed. Results of previous clinical chemoprevention trials in populations exposed to asbestos and considerations regarding future trials are also presented.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"53-57"},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11115283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141089410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Entering the golden age for antibody-drug conjugates in gynecologic cancer. 进入妇科癌症抗体药物结合的黄金时代。
Oncoscience Pub Date : 2024-05-20 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.604
Michelle Greenman, Blair McNamara, Levent Mutlu, Alessandro D Santin
{"title":"Entering the golden age for antibody-drug conjugates in gynecologic cancer.","authors":"Michelle Greenman, Blair McNamara, Levent Mutlu, Alessandro D Santin","doi":"10.18632/oncoscience.604","DOIUrl":"10.18632/oncoscience.604","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"51-52"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Erk5 expressed in bone marrow mesenchymal stem cells on bone homeostasis and its potential applications in cancer treatment. 骨髓间充质干细胞中表达的 Erk5 对骨稳态的作用及其在癌症治疗中的潜在应用。
Oncoscience Pub Date : 2024-05-20 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.601
Tetsuhiro Horie, Eiichi Hinoi
{"title":"Role of Erk5 expressed in bone marrow mesenchymal stem cells on bone homeostasis and its potential applications in cancer treatment.","authors":"Tetsuhiro Horie, Eiichi Hinoi","doi":"10.18632/oncoscience.601","DOIUrl":"10.18632/oncoscience.601","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"45-46"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary hepatic angiosarcoma: Treatment options for a rare tumor. 原发性肝血管肉瘤：罕见肿瘤的治疗方案。
Oncoscience Pub Date : 2024-05-20 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.602
Gregory L Guzik, Ankit Mangla
{"title":"Primary hepatic angiosarcoma: Treatment options for a rare tumor.","authors":"Gregory L Guzik, Ankit Mangla","doi":"10.18632/oncoscience.602","DOIUrl":"10.18632/oncoscience.602","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"47-48"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信